DelveInsight’s ‘Minimal Residual Disease (MSA) Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Minimal Residual Disease, historical and forecasted epidemiology as well as the Minimal Residual Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.The Minimal Residual Disease market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Minimal Residual Disease market size from 2019 to 2032. The Report also covers current Minimal Residual Disease treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Minimal Residual Disease Overview
Minimal Residual Disease (MRD) is a small number of cancer cells left in the body after treatment. These cells have the potential to come back and cause relapse. In leukemia, for example, physicians look for a response after chemotherapy treatment by looking under the microscope for cancer cells present in a bone marrow biopsy. An MRD positive test result means that the disease was still detected after treatment. An MRD-negative result means that no disease was detected after treatment. For patients who are MRD positive, the number of remaining cancer cells may be so small that they cannot be detected through traditional tests, such as viewing cells under a microscope. After treating cancer, any remaining cancer cells in the body can become active and multiply, causing a relapse of the disease. Detecting MRD may indicate that the treatment was not completely effective or that the treatment was incomplete.
Minimal Residual Disease Epidemiology Insights:
In the year 2021, the total minimal residual disease testing cases in the 7MM were found to be 1,219,739. The most number of MRD testing cases were found in the US followed by Germany.
The number of cases for MRD based on different cancer type was found to be 6,049, 18,396, 18,229, 7,884, 895, and 74,672 for ALL (Acute lymphoblastic leukemia), CLL (Chronic lymphocytic leukemia), AML (Acute myeloid leukemia), CML (Chronic myeloid leukemia), MM (Multiple myeloma), and Lymphoma respectively in the year 2021 in the United States.
In the 7MM total number of MRD testing by blood cancers was found to be 98,720, 368,298, 339,478, 149,497, 15,992, and 247,754 for ALL, CLL, AML, CML, MM, and Lymphoma respectively in the year 2021.
The total number of MRD testing for HSCT-related transplant in EU-5 were found to be 134,386 in the year 2021.
In Germany, the total number of MRD testing during new therapy and maintenance were found to be 38,501 and 96,925 respectively in the year 2021.
In Japan, age-wise MRD testing for pediatric and adult was found to be 13,428 and 97,753 respectively in 2021.
Minimal Residual Disease Epidemiology Segmentation
Total MRD testing
Total MRD cases by cancer type
Total MRD testing from different blood cancers
Total MRD testing for HSCT-related transplant
Total number of MRD Testing
Total MRD testing during new therapy and maintenance therapy
Minimal Residual Disease Market Outlook
The Minimal Residual Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Minimal Residual Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.This segment gives a thorough detail of the Minimal Residual Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Learn more by requesting for sample @ Minimal Residual Disease Market Trends
Minimal Residual Disease Key Companies
Adaptive Biotechnologies
Foresight Diagnostics
Cergentis B.V.
ICON plc
And many others
Minimal Residual Disease Key Therapy
Ampreloxetine (TD-9855)
Lu AF82422
Drug: TAK-341
Drug: Verdiperstat
Drug: Lu AF82422
Table of Contents
Key Insights
Report Introduction
Executive Summary of Minimal Residual Disease
Disease Background and Overview
Epidemiology and patient population
The United States
EU 5
Minimal Residual Disease Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Minimal Residual Disease Report Methodology
DelveInsight Capabilities
Disclaimer
Click here to read more about Minimal Residual Disease Market Trends
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
